Consolidated Revenue CAGR of at Least 3% and Operating Margin of at Least 15%
First written in FY2017. 4 of 8 entries say "Worsened", first in FY2018. Latest entry: FY2020.
KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2018, 5 years before the typical company in this theme (2023).
10 other companies' latest entry also says "Worsened".
- FY2020WorsenedAnnual report
「Against the original numerical targets of a consolidated sales CAGR of 3% or higher and a consolidated operating margin of 15% or higher, the consolidated sales CAGR was negative 2.0% and the consolidated operating margin was 6.8%, meaning the targets were not achieved.」
The results for the Stage 2 targets of a sales CAGR of 3% or higher and an operating margin of 15% or higher were negative 2.0% and 6.8%, respectively, and were explicitly identified as below target. - FY2020-Q1RestatedAnnual report
「In the fiscal year under review, the final year of the medium-term management plan, “HOPE100—Stage 2— (fiscal 2016–fiscal 2019),” the Group has adopted “Executing transformation by demonstrating the strength to see things through” as its management policy, and will maintain a mindset of never giving up until the end, devote maximum effort to achieving its targets, and」
The policy of pursuing the Stage 2 numerical targets through the final year and devoting maximum effort to achieving them continues. - FY2019WorsenedAnnual report
「Annual consolidated sales in the fiscal year under review increased 2.7% from the previous fiscal year, while the consolidated operating margin was 7.9%. Over the period covered by the medium-term management plan, “HOPE100—Stage 2—,” the consolidated sales CAGR is forecast at negative 1.1% and the consolidated operating margin at 8.0%.」
Although annual sales increased, the sales CAGR over the Stage 2 period is forecast at negative 1.1% and the operating margin at 8.0%, below the targets of 3% or higher and 15% or higher. - FY2019-Q3RestatedAnnual report
「There are no changes to the business strategy or numerical targets for achieving the medium-term management plan, “HOPE100—Stage 2—.”」
The Group expressly states that the business strategies and numerical targets for Stage 2 remain unchanged. - FY2019-Q2RestatedAnnual report
「There are no changes to the business strategy or numerical targets for achieving the medium-term management plan, “HOPE100—Stage 2—.”」
The Group expressly states that the business strategies and numerical targets for Stage 2 remain unchanged. - FY2019-Q1WorsenedAnnual report
「Total sales were ¥25.131 billion, down ¥1.327 billion, or 5.0%, year on year. Operating profit was ¥1.320 billion, a decline of ¥1.275 billion, or 49.1%, year on year.」
While maintaining the Stage 2 numerical targets, sales declined 5.0% year on year and operating profit fell 49.1% in the first quarter. - FY2018WorsenedAnnual report
「The medium-term management plan, “HOPE100—Stage 2—,” sets numerical targets of a consolidated sales CAGR of 3% or higher and a consolidated operating margin of 15% or higher. In the fiscal year under review, consolidated sales declined 4.1% from the previous fiscal year, while the consolidated operating margin was 8.0%.」
While reaffirming the numerical targets, the disclosure states that sales declined 4.1% from the previous fiscal year and that the operating margin was 8.0% in the fiscal year under review. - FY2017First statedAnnual report
「The medium-term management plan, “HOPE100 – Stage 2 –,” sets numerical targets of a consolidated revenue CAGR of at least 3% and an operating margin of at least 15% from FY2016 through FY2019, the final year of the plan.」
The Stage 2 numerical targets for FY2016 through FY2019 are stated for the first time: revenue growth and operating margin.